Last edition
News about "Newron Pharmaceuticals"
Newron Provides Update Following Type A Meeting with the US FDA
Newron has provided an update following its Type A meeting with the US Food and Drug Administration (FDA), outlining the steps required to resume US enrollment in the phase 3 ENIGMA-TRS 2 schizophrenia study.
Newron Pharmaceuticals | 04/07/2026 | By News Bureau | 108
Newron Pharmaceuticals Pauses US Enrollment in ENIGMA-TRS 2 Study
Newron Pharmaceuticals pauses enrolment at US sites in ENIGMA-TRS 2 study, while global ENIGMA-TRS 1 trial continues with more than 400 patients enrolled.
Newron Pharmaceuticals | 02/05/2026 | By News Bureau | 109
Newron Pharmaceuticals Secures Euro 38 Million to Advance Phase III Schizophrenia Programme
Newron Pharmaceuticals strengthens its funding base with a multi-tranche equity raise to support late-stage development of evenamide in treatment-resistant schizophrenia.
Newron Pharmaceuticals | 17/02/2026 | By News Bureau | 157
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy